Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 single-arm phase 2 study in relapsed/refractory or suboptimal-response AL amyloidosis
ChiCTR2500095465Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gamgertamig in light-chain amyloidosis, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Adverse events and serious adverse events and Rate of achieving very good partial response or better hematologic response after 4 cycles. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
gamgertamig
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ChiCTR2500095465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095465.